Sistema de Salut de Catalunya
Institut Català de la Salut
Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
Vall d'Hebron Barcelona Hospital Campus
2022-06-28T10:40:27Z
2022-06-28T10:40:27Z
2021-08-15
Antibody–Drug Conjugates; Cancer treatment
Conjugats anticossos-fàrmacs; Tractament contra el càncer
Conjugados anticuerpo-fármaco; Tratamiento contra el cáncer
Cross-reactivity with normal tissues is one of the key concerns for target selection for antibody–drug conjugates. Probody therapeutics are masked antibodies that can selectively be activated by proteases in the tumor. CX-2029, is a first-in-class Probody targeting CD71 with preliminary efficacy and a tolerable safety profile
Article
Published version
English
Càncer - Tractament; Medicaments - Alliberament retardat; Anticossos monoclonals - Ús terapèutic; DISEASES::Neoplasms; Other subheadings::Other subheadings::Other subheadings::/drug therapy; CHEMICALS AND DRUGS::Pharmaceutical Preparations::Prodrugs; CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Serum Globulins::Immunoglobulins::Antibodies::Immunoconjugates; ENFERMEDADES::neoplasias; Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia; COMPUESTOS QUÍMICOS Y DROGAS::preparados farmacéuticos::profármacos; COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::globulinas séricas::inmunoglobulinas::anticuerpos::inmunoconjugados
American Association for Cancer Research
Clinical Cancer Research;27(16)
https://doi.org/10.1158/1078-0432.CCR-21-1353
Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
Articles científics - HVH [3439]
